BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

# Nutricia, USV and AstraZeneca lead shift toward chronic and sub-chronic therapies in IPM

09 March 2026 | News

**Non-communicable diseases in the overall healthcare landscape expected to expand further**



Among the top 40 companies in the Indian Pharma Market (IPM), a few organisations stand out for their strong focus on chronic and sub-chronic therapies. Companies such as Nutricia, USV, AstraZeneca, Eris Lifesciences, and Intas Pharmaceuticals have a significant proportion of their portfolios concentrated in chronic and sub-chronic segments, highlighting their strategic emphasis on long-term disease management and lifestyle-related therapies.

Nutricia leads the list with 100 per cent of its portfolio coming from chronic and sub-chronic therapies, making it one of the most focused players in this space. The company's portfolio is largely aligned with specialised nutrition and long-term disease management, positioning it strongly in therapies that require sustained patient care.

USV follows closely with 96 per cent of its portfolio in chronic and sub-chronic therapies, driven by its strong presence in therapeutic areas such as diabetes and cardiology. AstraZeneca has about 85 per cent of its portfolio in these segments, supported by its focus on oncology, cardiovascular, and metabolic disorders.

Similarly, Eris Lifesciences derives around 83 per cent of its portfolio from chronic and sub-chronic therapies, reflecting its strategic focus on cardiometabolic and lifestyle disease treatments. Intas Pharmaceuticals also demonstrates a strong orientation toward long-term therapies, with approximately 79 per cent of its portfolio coming from chronic and sub-chronic segments, supported by its presence in oncology, cardiology, and central nervous system therapies.

Looking ahead, Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies noted that the role of non-communicable diseases in the overall healthcare landscape is expected to expand further. It is estimated that by 2026, non-communicable diseases could account for nearly 70 per cent of the disease burden, reinforcing the continued shift in the Indian pharmaceutical market toward chronic and sub-chronic therapies.

She further said that the strong focus of these companies on chronic and sub-chronic therapies mirrors the broader transformation underway in the Indian Pharma Market, where the growing burden of non-communicable diseases is driving sustained demand for long-term treatment solutions.